

1 Molecular evidence of coinfection with acute respiratory viruses and high
2 prevalence of SARS-CoV-2 among patients presenting flu-like illness in Bukavu
3 city, Democratic Republic of Congo

4 Patrick Bisimwa Ntagereka^{1*}, Rodrigue Ayagirwe Basengere¹, Tshass Chasinga Baharanyi^{2,3},
5 Théophile Mitima Kashosi^{1,2}, Jean-Paul Chikwanine Buhendwa^{2,4}, Parvine Basimane
6 Bisimwa^{2,4}, Aline Byabene Kusinza^{2,4}, Yannick Mugumaarhahama¹, Dieudonné Wasso
7 Shukuru¹, Simon Baenyi Patrick¹, Ronald Tonui⁵, Ahadi Bwihangane Birindwa¹, Denis
8 Mukwege^{2,6}

9
10 ¹*Université Evangélique en Afrique, Molecular Biology Laboratory, Bukavu Democratic*
11 *Republic of Congo*

12 ²*Université Evangélique en Afrique, Faculty of Medicine, Bukavu Democratic Republic of Congo*

13 ³*Panzi General Referral Hospital, Pathological Anatomy, Bukavu Democratic Republic of*
14 *Congo*

15 ⁴*Panzi General Referral Hospital, Department of Infectiology, Bukavu Democratic Republic of*
16 *Congo*

17 ⁵*Pan African University, Institute of Basic Sciences, Technology and Innovation, Department of*
18 *Molecular Biology and Biotechnology, Nairobi, Kenya*

19 ⁶*Panzi General Referral Hospital, Gynaecology and General Surgery, Bukavu Democratic*
20 *Republic of Congo*

21
22

23 **Corresponding author:** Patrick Bisimwa Ntagereka

24 Université Evangélique en Afrique, Molecular Biology Laboratory, Bukavu Democratic
25 Republic of Congo, PO Box 3323,

26
27 Email address: patrick.ntagereka@gmail.com

28
29

30 **Abstract**

31 The coronavirus 2019 (COVID-19) is caused by the severe acute respiratory syndrome
32 coronavirus 2 (SARS-CoV-2) with clinical manifestation cases are almost similar to those of
33 common respiratory viral infections. This study determined the prevalence of SARS-CoV-2 and
34 other acute respiratory viruses among patients with flu-like symptoms in Bukavu city
35 Democratic republic of Congo. We screened 1352 individuals with flu-like illnesses seeking
36 treatment in 10 health facilities. Nasopharyngeal swabs specimens were collected to detect
37 SARS-CoV-2 using real-time reverse transcription-polymerase chain reaction (RT-PCR) and 10
38 common respiratory viruses were detected by multiplex reverse transcription polymerase chain
39 reaction assay. Overall, 13.9% (188/1352) patients were confirmed positive for SARS-CoV-2.
40 Influenza A 5.6% (56/1352), and Influenza B 0.9% (12/1352) were the most common respiratory
41 viruses detected. Overall more than two cases of the other acute respiratory viruses were
42 detected. Frequently observed symptoms associated with SARS-CoV-2 positivity were shivering
43 (47.8%; OR= 1.8; CI: 0.88-1.35), cough (89.6%; OR=6.5, CI: 2.16-28.2), myalgia and dizziness
44 (59.7%; OR=2.7; CI: 1.36-5.85). Moreover, coinfection was observed in 12 (11.5%) specimens.
45 SARS-CoV-2, and Influenza A were the most co-occurring infections, accounting for 33.3% of
46 all positive cases. This study demonstrates cases of COVID-19 infections co-occurring with
47 other acute respiratory infections in Bukavu city during the ongoing outbreak of COVID-19.
48 These data emphasize the need for routine testing of multiple viral pathogens for better
49 prevention and treatment plans.

50 **Keywords:** SARS-CoV-2, respiratory viruses, flu-like symptoms, coinfection; Bukavu city.

51

52

53

54 1. INTRODUCTION

55 The world is facing a pandemic caused by the coronavirus disease 2019 (COVID-19), with over
56 136 million confirmed cases, including approximately 2,941,128 deaths globally as of Apr 13
57 2021¹. COVID-19 is caused by severe acute respiratory syndrome coronavirus 2

58 (SARS-CoV-2), a novel coronavirus, that emerged in Wuhan, China, in December 2019². SARS-
59 CoV-2 infection is generally asymptomatic³, although in most confirmed cases, it may manifest
60 itself with non-typical symptoms, including fever, cough, sore throat^{3,4,5}, which are known to be
61 present in common cold. Additionally, anosmia and ageusia may be observed^{6,7}.

62 The Democratic Republic of the Congo (DRC), with an estimated population of 86 million,
63 reported the first COVID-19 case on March 10, 2020, in Kinshasa city. While in Bukavu, a city
64 whose population is estimated above 1.13 million, registered the first case of COVID-19 from
65 arriving travelers in March 2020. Due to delay in quarantine measures and the failure in applying
66 ministry of health guidelines for containment of the pandemic, DRC had recorded 55774
67 confirmed cases and 1061 deaths as of 4th September 2021 in all 26 provinces, including South
68 Kivu.

69 South Kivu is characterized by a high population density, poor health infrastructure and limited
70 access to COVID-19 diagnostic tests. This places South Kivu among the high-risk provinces in
71 DRC. Previous studies have reported high seroprevalence of SARS-Cov-2 among health workers
72 and travelers in Bukavu city, suggesting a high circulation of SARS-CoV-2 within this city^{8,9}.

73 Diagnostic facilities for viral infections in DRC's provinces, and in particular South Kivu are
74 scarce. This prevents systematic screening of individuals who are asymptomatic or present mild
75 symptoms of COVID-19 (<https://ourworldindata.org/coronavirus-testing>). This challenge further
76 hampers strategies in the evaluation of the spread of SARS-CoV-2 within the population.

77 Currently, COVID-19 ‘gold’ test, which entails reverse transcription-polymerase chain reaction
78 (RT-PCR) as recommended by World Health Organization^{3,10}, focuses on symptomatic cases,
79 and hence, accurate estimate of the incidence cannot be obtained.

80 The research on the clinical characteristics of COVID-19 in most African countries has shown
81 that fever and cough are the most common symptoms associated with COVID-19 diagnosis.
82 Aside from these signs, fatigue, difficulty in breathing, sore throat, headache, and other atypical
83 symptoms have been reported.

84 The glaring similarity between these clinical signs with those of other respiratory viral
85 infections¹¹ reduces the diagnostic efficiency and treatment of COVID-19 cases. This may lead
86 to regular epidemics with pneumonia and bronchitis cases, severe respiratory failure, and even
87 death¹².

88 As the COVID-19 cases continue to rise, several cases of flu-like illness have been reported in
89 Bukavu city by the Provincial Ministry of Health from December 2020 to April 2021.

90 Therefore, identifying SARS-CoV-2 and pathogens responsible for respiratory infections is key
91 in the prevention of COVID-19 spread. This could improve patient management and reduce
92 patient isolation duration, particularly for those infected with other common respiratory viruses.

93 Thus, this study investigated the prevalence of SARS-CoV-2, Influenza A and B, and other acute
94 respiratory viruses among local patients with flu-like symptoms. These include but were not
95 limited to patients presenting a sudden onset of a fever of (>38 °C) and a cough or sore throat
96 who were seeking treatment at different health structures in Bukavu city.

97

98

99

100 **2. METHODS**

101 **2.1 Study area**

102 This study was carried out in Bukavu, the capital city of South Kivu province in eastern DRC.
103 The city is lying at the extreme south-western edge of Lake Kivu and separated from Rwanda by
104 the outlet of the Ruzizi River. As of 2020, Bukavu had an estimated urban population of
105 1,133,371. (<https://populationstat.com/democratic-republic-of-the-congo/bukavu>). Moreover, the
106 city is characterized by a tropical wet and dry climate with 1498 m of altitude above sea level
107 and an average rainfall of about 1224 mm annually. Patients were recruited from December
108 2020 to May 2021 in 10 health facilities such as BIOPHARM Health Centre, Panzi General
109 Reference Hospital, Saint Vincent polyclinic, MUHUNGU Health Centre, DIOCESAIN Centre,
110 Saint Luc polyclinic, 5th CELPA Health Centre, SOS Medical Centre, Nyantende Hospital, and
111 CHAI Health Centre.

112 **2.2 Study design, participants, and sample collection**

113 A cross-sectional study was adopted. Collection of swab samples to confirm COVID-19 disease
114 among patients with flu-like symptoms defined as an outpatient with a sudden onset of a fever
115 >38 °C, a cough or sore throat seeking treatment at the different health facilities. Only
116 individuals with flu-like disease symptoms, aged ten years and above, and able to give consent
117 were considered for sample collection the interview. Personal data such as age, sex, occupation,
118 and residence were recorded prior to collecting oropharyngeal swab samples. Collected samples
119 were put in a 2ml tube containing 2 milliliters of Sample Storage Reagent (Ansure,

120 Biotechnology) composed of 0.9% of normal saline raisin, and stored in -40°C before SARS-
121 CoV-2 Reverse Transcriptase Polymerase Chain Reaction amplification.

122 A total of 1352 Oropharyngeal samples were collected and shipped daily in ice to the Molecular
123 Biology laboratory of the Université Evangélique en Afrique (UEA). The data collection
124 followed ethical guidelines applied for human biological data collection and processing during
125 the study.

126 **2.3 Molecular detection of SARS-CoV-2**

127 Viral RNA was extracted from swabs samples within 1–24 hours following sample collection
128 using innuPREP Virus TS RNA kit (Analytik Jena, Berlin, Germany) according to the
129 manufacturer's instructions. The real-time reverse transcriptase-polymerase chain reaction (RT-
130 PCR) tests for SARS-CoV-2 were performed using TIB MOLBIOL Sarbeco E-gene Plus EAV
131 PCR Kit (Olfert Landt, Berlin Germany). Briefly, this entailed a 20 µL reaction mix comprising
132 10 µL of 2x Reverse transcriptase master Mix, 0.5 µL of extraction control EAV, 0.5 µL of PSR
133 reagent (SARS-CoV-2 probes and primers mix targeting the viral E gene), 5 µL of the extracted
134 RNA and the volume was adjusted to 20 µL with nuclease free water.

135 The cDNA synthesis step was conducted by incubating the mixture at 55°C for 5 minutes. RT-
136 PCR reactions with an initial denaturation step at 95°C for 5 min, followed by cycling steps of
137 95°C for 5 seconds, primer annealing at 60°C for 15 seconds, and an extension step of 72°C for
138 15 seconds. All the RT-PCR reactions were carried out in LightCycler® 96 Instrument (Roche,
139 Life Science). A sample was considered positive if the threshold (Ct value) is <35 while any
140 sample with threshold (Ct value) >35 was considered as negative.

141 **2.4 Detection of common acute respiratory viruses by Multiplex RT-PCR assays**

142 Each RNA sample was subjected to multiplex RT-PCR amplification using the ARVI Screen
143 Real-TM Multiplex Detection kit (Sacace Biotechnology, Italy) on a Lightcycler 96 detection
144 system (Roche, Germany). The panel was specifically developed to identify ten viruses including
145 human respiratory syncytial virus (hRSV); human metapneumovirus (hMpV); human
146 parainfluenza virus-1-4 (hPiv-1-4), OC43, E229, NL63 and HKUI human coronavirus (hCov);
147 human rhinovirus (hRv); human B, C, and E adenovirus (hAdv), human bocavirus (hBov) as
148 well as Influenza A and B within 1hour. The assay comprised reverse transcription and multiplex
149 RT-PCR Amplification.

150 The cDNA synthesis was performed in a 40 μ L mix containing 5 μ L RT-G-mix-1, 6 μ L of Reverse
151 transcriptase (M-MLV), 9 μ L of RT-Mix, and 20 μ L of RNA as a template. The cDNA libraries
152 were constructed by incubating the reaction mix at 37°C for 30 minutes in PeQlab thermocycler,
153 (peqSTAR, VWR). The cDNA samples were diluted in half with T.E. buffer for immediate use
154 in multiplex RT-PCR amplification or storage at -20°C for future analysis.

155 In addition, the multiplex Real-Time amplification setup was carried. Each mix contained
156 primers directed against regions of acute respiratory viral infection (ARVI). For each mix, three
157 controls were also included, such as negative, positive and internal control.

158 Real-time RT-PCR assays were performed in a 25 μ L reaction comprising 10 μ L of PCR-mix 1
159 containing specific primers for each virus, 5 μ L of PCR-Mix-FRT and 10 μ L of template cDNA.
160 The cycling parameters entailed 95 °C initial denaturation for 15 min followed by 40 cycles of
161 95 °C denaturation for 10s, 54°C annealing for 25s and extension at 72 °C for 25s. We set our
162 threshold value for positive cases of ARVI pathogens at any value less than 35.

163 The negative cases of an ARVI were assessed when the threshold value (Ct) of the tested sample
164 is absent (not determined) or if the Ct value exceeds 35.

165

166 **2.5 Data analysis**

167 Collected data were encoded in Microsoft® Excel® data management tool combining the results
168 of SARS-CoV-2 RT-PCR and other respiratory virus assays and data obtained from the
169 questionnaire. Prior to statistical analyses, all personal identification data were eliminated.
170 Descriptive statistics were calculated for all of the variables, including the RT-PCR prevalence
171 results. We assessed the associations between SARS-CoV-2 and other respiratory viruses RT-
172 PCR results (positive or negative) with age, sex, symptom, exposure and morbidity using the
173 Chi-Squared test. The odds of being a positive case based on RT-PCR results were then
174 modeled as a function of the dichotomous risk factors measures, using logistic regression
175 models. All variables with p-values of ≤ 0.05 were considered statistically significant. The R.
176 Console statistic software (version 4.0.0) was used to perform the analysis.

177

178

179

180

181

182

183

184

185

186

187

188

189 **3. RESULTS**

190 **3.1 SARS-CoV-2 and common acute respiratory infection prevalence and associated**

191 **Symptoms in patients with flu-like symptoms from nine health structures**

192 In total, 1352 individuals presenting flu-like illness were examined, all of whom resided in the
193 Bukavu city. Among these were 696 males (51.4%) and 656 females (48.5%). The majority
194 (89.6%) being adults. A high proportion (63.3%) were those recorded in BIOPHARM medical
195 center. The SARS-CoV-2 was detected in 188 representing a positivity rate of 13.9%. The
196 prevalence of SARS-CoV-2 was higher in females (14.6 %) compared to males (13.3%). The age
197 range of the SARS-CoV-2-positive patients was 176(14.5%) out 1212 adults and 12(8.6%) in
198 young (less than 18 years).out of 140.

199 Influenza A and B viruses were diagnosed respectively in 76 (5.6%) and in 12 (0.9%) samples.
200 Multiplex RT-PCR test detected Human parainfluenza 1-4 (hPiV 1-4) in 10 (0.7%) patients
201 while human Metapneumonia virus (hMpv) was present in 5 (0.4%) patients. Additionally,
202 human Coronavirus (hCoV), human Rhinovirus (hRV) and human Adenovirus (hAdV) were
203 identified in 3 (0.2%) samples for each while only 1(0.07%) patient was identified to be infected
204 with Human Bocovirus (hBoV).

205 Of all health facilities, Panzi General Reference (Panzi HGRP) recorded the highest SARS-CoV-
206 2, 12 (23.1%), and influenza B 4 (7.7%) cases (Table 1).

207 **TABLE 1** Frequency of SARS-CoV-2 and other respiratory viruses detected according to sex, age and health facility

Variables	Number sampled	SARS-CoV-2 +	INFL. A +	INFL. B +	hMpv	hPiV 1-4	hCoV	hRV	hAdV	hBoV
Gender										
F	696	101(14.6%)	40(5.8 %)	8(1.2 %)	3(0.4 %)	7(1.0 %)	1(0.1 %)	2(0.3%)	1(0.1%)	1(0.1%)
M	656	87(13.3%)	36(5.5%)	4(0.6 %)	2(0.3 %)	3(0.5 %)	2(0.3 %)	1(0.2%)	2(0.3 %)	0(0 %)
Age range										
Adult	1212	176(14.5%)	60(5.0%)	12(1.0 %)	4(0.3 %)	8(0.7 %)	3(0.2 %)	3(0.2)	3(0.2 %)	1(0.1 %)
Young	140	12(8.6%)	12(8.6%)	0(0 %)	1(0.7 %)	2(1.4 %)	0(0%)	0 (0%)	0(0%)	0(0%)
Health structures										
Biopharm HC	856	116(13.6%)	48(5.6%)	4(0.5 %)	1(0.1 %)	4(0.5 %)	0(0 %)	0(0%)	0(0%)	1 (0.1%)
5 th CELPA HC	72	8(11.1%)	4(5.6 %)	0(0 %)	1 (1.4%)	2(2.8%)	1(1.4 %)	1(1.4%)	2(2.8%)	0(0%)
Panzi GRH	52	12(23.1%)	0(0%)	4(7.7%)	2(3.8%)	0(0%)	2 (3.8 %)	0 (0%)	0(0%)	0(0%)
CHAI HC	64	4(6.3%)	4 (6.3 %)	0(0 %)	0 (0)	0 (0 %)	0 (0 %)	0 (0 %)	0(0 %)	0(0 %)
SOS HC	88	16(18.2%)	4(4.5%)	0 (0%)	0 (0 %)	0 (0 %)	0 (0 %)	0 (0 %)	0(0%)	0(0%)

Nyantede Hospital	76	12(15.8%)	4(5.3%)	0(0 %)	0 (0 %)	0(0 %)	0 (0 %)	1(1.3 %)	0(0%)	0(0%)
Muhungu dios.HC	20	4(20.0 %)	0(0%)	0(0%)	0(0%)	0 (0%)	0(0%)	0(0%)	0(0%)	0(0%)
St Luc HC	24	8(33.3 %)	4(16.7 %)	0(0 %)	1 (4.2%)	2(8.3%)	0(0%)	1(4.2%)	1(4.2%)	0(0%)
Muhungu HC	28	8(2.9 %)	4(1.4 %)	4(1.4%)	0(0%)	2 (0.7%)	0(0%)	0(0%)	0(0%)	0(0%)
Total N (%)	1352	188 (13.9)	76 (5.6)	12 (0.9)	5(0.4)	10(0.7)	3(0.2)	3(0.2)	3(0.2)	1(0.07)

208

209

210

211 **3.2 Profiles of SARS-CoV-2 and other respiratory infection positive patients and associated**
212 **clinical symptoms**

213 The most frequent symptom in COVID-19 was coughing (89.6%), followed by headaches 1049
214 (77.6%), asthenia 909 (67.2%), high fever 706 (52.2%), as well as myalgia (59.7%).
215 Hypertension 122(9%), obesity 81(6%), and diabetes 81(6%) were the most frequently reported
216 comorbidities in COVID-19 positive individuals. More than half of influenza A-positive patients
217 experienced fever, cough, and headache and were asthenia, hypertensive and diabetics. However,
218 all influenza B infected patients experienced headaches (100%) while more than half presented
219 fever, coldness, cough, breathing difficulties, asthenia, myalgia, anorexia, and sputum
220 **(Supplementary materials Table 1)**. The statistical analysis revealed statistically significant
221 association between COVID-19 with some symptoms such as shivering (47%.8%; OR= 1.8; CI:
222 0.88-1.35; p=0.024), cough (89.6%; OR=6.5, CI=2.16-28.2; p=0.003), myalgia and dizziness
223 (59.7%; OR=2.7; CI: 1.36-5.85, p=0.006) (Table 2).

224 Comparative analysis between SARS-CoV-2 positive and negative individuals showed that
225 patients who have been in contact with infected persons presented a higher risk of being infected
226 by SARS-CoV-2 were the one with close contact (OR=2.40; CI: 0.43-13.45), followed workers
227 in hospitals (OR=1.78; CI: 0.34-8.43) and patient with diabetes (OR=1.17; CI: 0.29-3.93) than
228 negative individuals. However, none of these factors were statistically significant. Additionally,
229 no statistical difference was found between gender and commodities variables when compared
230 SARS-CoV-2 and negative patients (p<0.05) (Table 2).

231

232

233 **TABLE 2:** Association of flu-like symptoms with SARS-CoV-2 positivity among flu-like patients seeking
 234 treatment in different health facilities

Variables	Negative covid19 N= 1164(%)	Positive Covid19 N= 188(%)	OR (CI)	p value
Symptoms (%)				
Fever	512 (44.1%)	98 (52.2%)	1.1 (0.560-2.282)	0.734
Coldness	531 (45.6%)	98 (52.2%)	0.9 (0.456- 1.856)	0.816
Shivering	371 (31.9%)	88 (47.8%)	1.8 (0.88 - 1.35)	0.0246**
Sweating	268(23.0%)	56 (29.9%)	1.3 (0.603- 3.69)	0.452
Cough	764(65.6%)	168 (89.6%)	6.5 (2.161- 28.207)	0.003***
Breathing difficulties	271(23.3%)	45 (23.9%)	0.7 (0.321-1.814)	0.590
Essoufflés	233(20.0%)	17 (9.0%)	0.3(0.107-1.094)	0.0992
Headaches	793(68.1%)	146 (77.6%)	1.6 (0.738-3.821)	0.242
Asthenia	560(56.7%)	126 (67.2%)	1.6(0.804-3.487)	3.487
Myalgia	478(41.1%)	112 (59.7%)	2.7(1.363-5.859)	0.006***
Anorexia	314(27.0%)	73 (38.8%)	1.5 (0.743-3.283)	0.232
Sputum	194(16.7%)	42 (22.4%)	0.8(0.360-1.926)	0.716
Dyspnea	164(14.1%)	19 (10.4%)	0.6 (0.236-1.772)	0.461
Expositions (%)				
Stay in high risk areas	116 (10.0)	33 (17.9)	1.09 (0.31- 2.81)	0.85
Close contact	48 (4.1)	11 (6.0)	2.40 (0.43-13.45)	0.29
Work in hospitals	81 (7.0)	17 (9.0)	1.78 (0.34-8.43)	0.46
Comorbidities (%)				
HIV infection	8 (0.7)	0 (0.0)	-	-
Arterial hypertension	112 (9.6)	17 (9.0)	0.82 (0.21-2.57)	0.75
Obesity	30 (2.6)	11 (6.0)	0.76 (0.03-6.16)	0.81
Diabetes	69(5.9)	11 (6.0)	1.17 (0.29-3.93)	0.80
Chronic respiratory dis.	26 (2.2)	3 (1.5)	0.56 (0.02-3.97)	0.61
Cardio pathology	8 (0.7)	0 (0.0)	-	-
Chronic kidney dis.	13 (1.1)	0 (0.0)	-	-
Nero pathology	5 (0.4)	1.5	0.00 (0.00-0.001)	0.98

235 ***: highly significant; **: Very significant; *: Significant

236

237 3.3 Logistic regression analysis for factors associated with Influenza A and B positivity

238 The logistic regression analysis revealed that 53.3% (OR=1.51; IC=0.46-4.98) of Influenza A

239 negative patients were inversely correlated with cold compared with 16.7% in influenza A
240 positive patients. However, there were no significant differences in other factors for influenza A
241 and B infection rates ($p > 0.05$) (Table 3).

242 **TABLE 3:** Logistic regression analysis regarding demographical gender, exposition and comorbidity between positive Influenza A
 243 and B patients

	<i>INFL A</i>		<i>INFL. A</i>		<i>INFL B</i>		<i>INFL. B</i>	
	<i>Neg.</i> (<i>N=1276</i>)	<i>Pos.</i> (<i>N=76</i>)	<i>OR (IC)</i>	<i>p</i>	<i>Neg.</i> (<i>N=1340</i>)	<i>Pos.</i> (<i>N=12</i>)	<i>OR (IC)</i>	<i>p</i>
<i>Symptoms (%)</i>								
Fever	48.2	58.3	1.51 (0.46-4.98)	0.558	49.0	51.2	1.04 (0.21, 5.22)	1.000
Coldness feeling	53.3	16.7	0.18 (0.04-0.83)	0.017**	50.3	51.5	0.99 (0.20, 4.94)	1.000
Shivering	40.1	25.0	0.50 (0.13-1.92)	0.369	38.8	51.5	1.58 (0.32, 7.91)	0.682
Sweating	24.8	25.0	1.01 (0.26-3.95)	1.000	25.2	0.0	-	-
Cough	77.4	58.3	0.41 (0.12-1.38)	0.163	76.2	51.3	0.31 (0.06, 1.57)	0.155
Breathing difficulties	22.6	25.0	1.14 (0.29-4.47)	1.000	22.4	51.2	3.45 (0.69, 17.38)	0.135
Essoufflés	16.1	25.0	1.74 (0.44-6.95)	0.425	17.0	0.0	-	-
Headaches	71.5	66.7	0.80 (0.23-2.80)	0.745	70.7	100.0	-	-
Asthenia	59.1	50.0	0.69 (0.21-2.25)	0.556	58.5	51.5	0.71 (0.14, 3.55)	0.697
Myalgia	48.9	25.0	0.35 (0.09-1.34)	0.139	46.9	51.5	1.13 (0.23, 5.66)	1.000
Anorexia	31.4	25.0	0.73 (0.19-2.83)	0.755	30.6	51.5	2.27 (0.45, 11.37)	0.379
Sputum	25.5	8.3	0.26 (0.03-2.13)	0.295	23.8	51.1	3.20 (0.64, 16.09)	0.155
Dyspnea	16.1	25.0	1.74 (0.44-6.95)	0.425	17.0	0.0	-	-
<i>Expositions (%)</i>								
Stay in high risk areas	14.6	16.7	1.17 (0.24-5.74)	0.692	15.0	0.0	-	-
Close contact	4.4	0.0	-	-	4.1	0.0	-	-
Work in hospitals	5.1	0.0	-	-	4.8	0.0	-	-
<i>Comorbidities</i>								

(%)									
Immunosuppression	0.7	0.0	-	-	0.7	0.0	-	-	-
Hypertension	9.5	16.7	1.91 (0.38-9.66)	0.346	10.2	0.0	-	-	-
Obesity	2.2	8.3	4.06 (0.39-42.37)	0.288	2.7	0.0	-	-	-
Diabete	7.3	16.7	2.54 (0.49-13.21)	0.249	8.2	0.0	-	-	-
Chronic Resp. dis.	3.6	0.0	-	-	3.4	0.0	-	-	-
Chronic Cardiac dis.	0.0	0.0	-	-	0.0	0.0	-	-	-
Chronic kidney dis.	0.7	0.0	-	-	0.7	0.0	-	-	-
Chronic liver dis.	0.0	0.0	-	-	0.0	0.0	-	-	-
Chronic neurologic dis.	0.7	0.0	-	-	0.7	0.0	-	-	-

244 **: Very significant

245

246

247

248 3.4 Coinfection patterns of COVID-19 and other acute respiratory viruses

249 During this investigation, it was found six coinfection patterns. Out of the 113 cases of infected
250 acute respiratory patients, 12 (11.5%) cases were co-infected with different acute respiratory
251 viruses. A high frequency of coinfections pathogens involved SARS-CoV-2 and Influenza A,
252 accounting for 33.3% of all coinfection cases. Additionally, 3 cases (25%) of hMPiV positive
253 cases were co-infected with hCoV followed by 2 cases (16.6%) of SARS-CoV-2 co-infected
254 with Influenza B (Table 4).

255 **TABLE 4:** Co-infection of SARS-CoV-2 with others respiratory viruses in Flu-like symptomatic patients

<i>Number</i>	<i>Virus types</i>	<i>Co-infectious viruses</i>	<i>Cases</i>
1	<i>hMPV+hPiV 1-4</i>	2	1
2	hMPV+hCoV	2	3
3	HBoV+Inf. A	2	1
4	SARS-CoV-2+Inf. B	2	2
5	SARS-CoV-2+Inf. A	2	4
6	SARS-CoV-2+hMPiV	2	1

256

257

258

259

260

261

262

263

264 **4. DISCUSSION**

265 COVID-19 first reports in DRC emerged towards the beginning of March 2020 and there has
266 been an upsurge of the cases ever since then nationally. SARS-COV-2 infections in South Kivu
267 province soared from April to December 2020. This is the period when flu-like illnesses peaks. It
268 was therefore vital to investigate the presence of SARS-CoV-2 among local patients with flu-like
269 illnesses seeking treatment in various health facilities. This may help us to better control the
270 epidemic outbreak and correctly handle other acute respiratory infections. Participants in this
271 study included 696 males (51.4%) and 656 females (48.5%). The majority were adults 1212
272 (89.6%).

273 In this study, a total of 188 participants were confirmed to be COVID-19 positives with
274 positivity rate of 13.9%. The infection rate found from this study is higher than the one found in
275 a previous study conducted in China where only 0.3% of patients with influenza-like illnesses
276 were found to be COVID-19 positive¹³. Similarly, these results are not consistent with the ones
277 reported in South Kivu, DRC, in which SARS-CoV-2 antibodies were detected in 148 (41.2%)
278 health workers from the Panzi General Reference Hospital (HGRP)⁹. This difference could
279 probably be explained by the type of test and study population. The previous study from HGRP
280 was detecting only antibodies (exposure) and focusing only on asymptomatic health workers
281 while in this study, we examined individuals presenting flu-like illness seeking treatment in
282 different health facilities.

283 In addition, 8.3% of the flu-like illness patients were tested positive for other respiratory viruses.
284 These results emphasize the importance of simultaneous diagnosis of other acute respiratory viral
285 pathogens, particularly in a mild epidemic area and during the current COVID-19 pandemic.

286 Among the acute respiratory viral pathogens, Influenza A and influenza B viruses were the most
287 detected respectively in 76 (5.6%) and 12 (0.9%) patients with flu-like symptoms and COVID-
288 19 negative. This infection rate is relatively lower than those reported in Shanghai in which
289 influenza A and B were detected in 40.4% and 14.3% of patient respectively¹⁴. In Chongqing,
290 65.7% cases of Influenza A and 34.1% of Influenza B were reported in individuals with flu-like
291 symptoms¹⁵. This differences could be explained by the difference in targeted population, the
292 previous was focused mostly while in the last study the majority were children and young
293 people. As the considered area face different agro-ecological conditions, this may lead to
294 different rate of infection. However, findings from this study are in agreement with a recent
295 study revealing a higher incidence of influenza infections in children and adolescents compared
296 to old individuals¹⁶.

297 Furthermore others respiratory pathogens were detected including hPiV 1-4, hPiV 1-4
298 10(0.7%), hMPiV 5(0.4) and the other virus with 3 cases (0.2%) each. Similar results were
299 obtained in different studies in Costa Rican and China¹⁷. In all the cases, adult persons tended to
300 be mostly affected compared to young people although no statistical differences were found.

301 A weak association was noted in patients infected with respiratory viruses and clinical signs such
302 as cough, headaches, asthenia, coldness feeling, fever, shivering, and myalgia. This result is in
303 agreement with the finding from Monto et al.¹⁸ that revealed cough associated with fever to be
304 the most frequent symptoms with influenza infection. However, our findings are inconsistent
305 with a previous study focused on clinical features of COVID-19 and Influenza, which
306 demonstrated that symptoms like anosmia, dysgeusia, diarrhea, frontal headache and bilateral
307 cracklings sounds were more frequent in COVID-19 while sputum production, dyspnea, sore
308 throat, conjunctivitis, hyperthermia, tearing, vomiting and rhonchi sounds were more frequent in

309 influenza infection¹⁹. A subsequent study with a larger sample and follow up of patients would
310 allow to establish clinical signs of similarities and differences between infection with COVID-19
311 and infection with other respiratory viruses. This can help practically in the areas under equipped
312 for the biological diagnosis.

313 In this study, gender and comorbidities did not significantly influence the COVID-19 rate. This
314 is similar with previous studies showed that gender was not associated with the SARS-CoV-2
315 infection rate^{20, 21}.

316 The risk of being infected by SARS-CoV-2 increased in patients who have been in contact with
317 diseased persons (OR=2.4). This is in accordance with the fact that in resource-limited areas,
318 including South Kivu province, quarantine of infected individuals often occurred at home,
319 enabling onwards transmission within households.

320 People of all ages are susceptible to SARS-CoV-2. However, previous findings have confirmed
321 that adults, specifically older men are more likely to be affected and subsequently suffer from
322 severe pneumonia, pulmonary oedema, acute respiratory distress syndrome, multiple organ
323 failure, and death^{5, 22,23}. Although it appeared that all ages of the population are susceptible to
324 SARS- CoV-2 infection, but the median age of infection was in adult persons (around 50 years).
325 This is in agreement with previous research revealing the median age of infection to be around
326 50 years²⁰, and considering the range of African population.

327 In general, there are no striking differences in the clinical behavior and severity between the
328 different Influenza A and B viruses affecting patients. The only significant clinical symptom
329 with negative relationship to Influenza A virus was feeling cold (OR= 0.18, p=0.017) where the
330 majority of influenza A negative individuals were feeling cold. Our data do not show differences
331 in clinical manifestation compared with other previous descriptions in the literature. However,

332 three clinical symptoms were relevant for Influenza A, including fever, cough, headache, feeling
333 cold. Similar results were reported in a previous study in Costa Rica¹⁶. Among the 12 patients
334 who were Influenza A type positive in our study, all (100%) had a headache, and more than half
335 presented the remaining symptoms such as Fever, Coldness, Shivering, Sweating, Cough,
336 Breathing difficulties, essoufflés, Asthenia, myalgia, anorexia, sputum, and Dyspnea. No
337 respiratory and cardiac failure was observed to be associated with Influenza infection. This result
338 is in contrast with previous studies that have reported 16% of cases of seasonal Influenza
339 occurring in clinical pulmonary patients²⁴ and 25.2% in cardiac failure²⁵.
340 Moreover, 12 (11.5%) cases co-infected with other acute respiratory viruses were reported. The
341 highest coinfections pathogens were SARS-CoV-2 and Influenza A, accounting for 33.3% of all
342 coinfection cases. The high coinfection rate between SARS-CoV-2 and Influenza virus can
343 probably be explained by restrictions in applying barrier measures such as wearing masks, hand
344 washing, social distance, and hand-sanitizing of infected person. This could further be due to the
345 seasonality nature of the influenza virus which peaks between December and April,
346 corresponding to the winter period. This observation is supported by a previous study conducted
347 by Leung et al.²⁶. However, our finding is in contrast with previous studies^{27,28} whose findings
348 show a decrease in seasonal influenza cases during the Covid-19 pandemic. In this regard, it
349 would be ideal to have the follow-up of patients co-infected with COVID-19 and other
350 respiratory viruses and to assess their evolution over time; this may also requires another
351 extended study for clinical follow-up of cases.

352 In addition, in this study, cases of hMPiV co-infected with hCoV were reported. These findings
353 are in accordance with previous studies suggesting the possible coinfections of multiple
354 respiratory viruses^{29, 30, 31,32}.

355 This study demonstrates cases of COVID-19 infections co-occurring with other acute respiratory
356 infections in DR Congo. These data on the coinfection of SARS-CoV-2 with respiratory viral
357 pathogens emphasize the need for routine testing of multiple viral pathogens in mild epidemic
358 areas during the current COVID-19 epidemic. Further study is need to evaluate clinical patient
359 with these co-infection and their evolution. Additionally, whether simultaneous viral infection in
360 SARS-CoV-2 patients can potentially drive viral interference or impact disease outcome need
361 further investigation.

362 **5. CONCLUSION**

363 This study analysed the epidemiological patterns of SARS-CoV-2 and different respiratory
364 viruses, and found a high infection rate with COVID-19 and cases of positive common acute
365 respiratory infections in patients presenting flu-like symptoms. Although the current pandemic
366 constitutes a serious public health concern, SARS-CoV-2 may not be considered to be the only
367 pathogen responsible for respiratory tract infection in South Kivu eastern of DRC. Therefore,
368 testing for respiratory viruses should be performed in all patients with respiratory symptoms for
369 effective surveillance of the transmission patterns in the COVID-19 affected areas for optimal
370 treatment to inhibit the rapid spread of the virus

371 **ETHICS STATEMENT**

372 The study protocol was approved by the Interdisciplinary Center of Ethical Research (CIRE) of
373 the Université Evangélique en Afrique (UEA), Ref: CNES 001/DPSK/115PP/2021. Informed
374 consent was obtained from all participants after being signed and the confidentiality of the data
375 was ensured.

376 **CONFLICT OF INTERESTS**

377 The authors declare that they have no competing interests.

378 **AUTHOR CONTRIBUTIONS**

379 Patrick Bisimwa Ntagereka completed study design, project administration, data collection,
380 drafted the manuscript.

381 Rodrigue Ayagirwe Basengere completed investigation, data curation, review and the editing the
382 manuscript.

383 Tshass Chasinga Baharanyi completed investigation, and review of the manuscript.

384 Théophile Mitima Kashosi completed data curation, review and editing of the manuscript.

385 Jean-Paul Chikwanine Buhendwa completed investigation, data collection review and editing.

386 Parvine Basimane Bisimwa completed conceptualization, writing, and original draft preparation.

387 Aline Byabene Kusunza, investigation, data collection review and editing of the manuscript

388 Yannick Mugumaarhahama completed formal analysis, visualization, writing, and original draft
389 preparation.

390 Dieudonne Wasso Shukuru completed conceptualization, data analysis, writing, review, and
391 editing.

392 Simon Baenyi Patrick completed formal analysis, data curation, writing, and original draft
393 preparation.

394 Ronald Tonui, completed formal analysis, visualization, writing, and original draft preparation.

395 Ahadi Bwihangane Birindwa completed investigation, data curation, review and editing of the
396 manuscript.

397 Denis Mukwege, supervised the study, completed project administration, writing, review, and
398 editing the manuscript. All authors approved the manuscript.

399 **ACKNOWLEDGMENTS**

400 We Acknowledge the Université Evangélique en Afrique (UEA) through the Bioscience unit and
401 German Institute for Medical Mission (DIFÄM) for the financial support. Our sincere
402 appreciation goes further to the Provincial Ministry of Health and all the leaders of health
403 structures for facilitating access to sample and data. We also thank you the lab technicians of the
404 Molecular Biology laboratory of UEA for their technical support.

405 **FUNDING SOURCE**

406 This work was partially supported by a grant from the German Institute for Medical Mission
407 (DIFÄM) and by the Université Evangélique en Afrique (UEA) under the grant number 2020-
408 610-CD titled “Projet de formations sur les méthodes de diagnostic de COVID-19 et
409 amélioration de la prise en charge clinique des cas graves”.

410

411

412

413

414

415

416 **REFERENCES**

- 417 1. World Health Organization (WHOa). Coronavirus disease (COVID- 19): Similarities and
418 differences with Influenza. Q&A (Mar 17 2020). (Accessed on Oct 25 2020). Available
419 from: [https://www.who.int/news-room/q-a-detail/coronavirus-disease-covid-19-
420 similarities-and-differences-with-influenza.](https://www.who.int/news-room/q-a-detail/coronavirus-disease-covid-19-similarities-and-differences-with-influenza)
- 421 2. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak
422 associated with a new coronavirus of probable bat origin. *Nature* 2020; 579, 270–273.
- 423 3. World Health Organization (WHOb). Laboratory testing for coronavirus disease 2019
424 (COVID-19) in suspected human cases, Interim guidance Mar 2 2020 [Internet]. 2020
425 [Cited 14/07/2020]. Available from:
426 [https://apps.who.int/iris/bitstream/handle/10665/331329/WHO-COVID-19-laboratory-
427 2020.4-eng.pdf?sequence=1&isAllowed=y.](https://apps.who.int/iris/bitstream/handle/10665/331329/WHO-COVID-19-laboratory-2020.4-eng.pdf?sequence=1&isAllowed=y) <https://doi.org/10.15585/mmwr.mm6942a5>
428 PMID: 33090982.
- 429 4. Jung CY, Park H, Kim DW, Choi YJ, Kim SW, Chang TI. Clinical characteristics of
430 asymptomatic patients with COVID-19: a Nationwide cohort study in South Korea. *Int J*
431 *Infect Dis* 2020; 99:266–8 Available from: [https://pubmed.ncbi.nlm.nih.gov/32771632.](https://pubmed.ncbi.nlm.nih.gov/32771632)
432 [https://doi.org/10.1016/j.ijid.2020.08.001.](https://doi.org/10.1016/j.ijid.2020.08.001)
- 433 5. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected
434 with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395(10223):497–506.
435 [https://doi.org/10.1016/S0140-6736\(20\)30183-5.](https://doi.org/10.1016/S0140-6736(20)30183-5)

- 436 6. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic manifestations of
437 hospitalized patients with coronavirus disease 2019 in Wuhan, China. *JAMA Neurol*
438 2020;77:683–90. <https://doi.org/10.1001/jamaneurol.2020.1127>.
- 439 7. Vaira LA, Salzano G, Deiana G, De Riu G. Anosmia and Ageusia: common findings in
440 COVID-19 patients. *Laryngoscope* 2020;130(7):1787. <https://doi.org/10.1002/lary.28692>.
- 441 8. Katchunga PB, Murhula A, Akilimali P, Zaluka JC, Karhikalembu R, Makombo M,
442 Bisimwa J, Mubalama E. Séroprévalence des anticorps anti-SARS-CoV-2 parmi les
443 voyageurs et travailleurs dépistés à la clinique Saint Luc de Bukavu, à l'Est de la
444 République Démocratique du Congo, de mai en août 2020. *Pan Afr Med J* 2021; 38:93.
445 10.11604/pamj.2021.38.93.26663.
- 446 9. Mukwege D, Kusunza BA, MunguAkonkwa E, Dahma H, Dauby N, Cikwanine JPB,
447 Coadou AL, Montesinos I, Bruyneel M Cadière GB, Vandenberg O, Laethem YV. High
448 SARS-CoV-2 Seroprevalence in Healthcare Workers in Bukavu, Eastern Democratic
449 Republic of Congo. *Am J Trop Med Hyg* 2021; 104(4), 1526–1530.
450 doi:10.4269/ajtmh.20-1526.
- 451 10. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DKW, et al. Detection of
452 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Euro Surveill.* 2020a; 25(3):
453 2000045. doi: 10.2807/1560-7917.ES.2020.25.3.2000045.
- 454 11. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX et al. Clinical characteristics of
455 coronavirus disease 2019 in China. *N Engl J Med* 2020; 30;382(18):1708–1720.
456 doi:10.1056/NEJMoa2002032. PubMed PMID: 32109013.
- 457 12. Finianos M, Issa R, Curran MD, Afif C, Rajab M, Irani J, Hakimeh N, Naous A, Hajj M-
458 J, Hajj P, et al. Etiology, seasonality, and clinical characterization of viral respiratory

- 459 infections among hospitalized children in Beirut, Lebanon. *J Med Virol*
460 2016;88(11):1874–81.
- 461 13. Kong WH, Li Y, Peng MW, Kong DG, Yang XB, Wang L, Liu MQ. SARS-CoV-2
462 detection in patients with influenza-like illness. *Nat Microbiol* 2020;
463 <https://doi.org/10.1038/s41564-020-0713-1>.
- 464 14. Kong DC, Wu HY, Zheng YX, Pan H, Jiang CY, Zhang X, Chen J, Wu F. Etiologic and
465 epidemiologic features of acute respiratory infections in adults from Shanghai, during
466 2015-2017]. *Zhonghua Liu Xing Bing Xue Za Zhi Chinese*. 2019; 10;40(8):904-910. doi:
467 10.3760/cma.j.issn.0254-6450.2019.08.007.
- 468 15. Qi L, Xiong Y, Xiao B, Tang W, Ling H, Long J, Xiao D, Zhao H, Ye S, Chen S, et al.
469 Epidemiological and Virological Characteristics of Influenza in Chongqing, China, 2011-
470 2015. *PLoS One*. 2016;11(12):e0167866.
- 471 16. Ávila-Moralesa S, Ospina-Henaob S, Ulloa-Gutierrez R, Ávila-Agüeroa ML.
472 Epidemiological and clinical profile between influenza A and B virus in Costa Rican
473 children. *Int J Infect Dis*; 2021; 105, 763–768.
- 474 17. Singh V, Upadhyay P, Reddy J, Granger J. SARS-CoV-2 respiratory coinfections:
475 Incidence of viral and bacterial co-pathogens *Int J Infect Dis* 2021; 105 617–620.
- 476 18. Monto AS, Gravenstein S, Elliott M, Colopy M, Schweinle J. Clinical signs and
477 symptoms predicting influenza infection. *Arch Intern Med* 2020; 160:(21), 3243-3247.
- 478 19. Zayet S, Lepiller Q, Zahra H, Royer PY, Toko L, Gendrin V, Klopfenstein T. Clinical
479 features of COVID-19 and influenza: a comparative study on Nord Franche-Comte
480 cluster. *Microbes and infect* 2020; 22(9), 481-488.

- 481 20. Wu Z and McGoogan JM. Characteristics of and important lessons from the coronavirus
482 disease 2019 (COVID-19) outbreak in china: summary of a report of 72314 cases from
483 the Chinese Center for Disease Control and Prevention. *JAMA* 2020; 323, 1239–1242.
- 484 21. Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan,
485 China: the mystery and the miracle. *J Med Virol* 2020; 92:401–402.
- 486 22. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical
487 characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a
488 descriptive study. *Lancet* 2020; 395:507–13.
- 489 23. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138
490 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China.
491 *JAMA* 2020; <https://doi.org/10.1001/jama.2020.1585>.
- 492 24. Casalino E, Antoniol S, Fidouh N, Choquet C, Lucet J-C, Duval X, et al. Influenza virus
493 infections among patients attending emergency department according to main reason to
494 presenting to ED. A 3-year prospective observational study during seasonal epidemic
495 periods. *PLoS ONE* 2017; 12(8): e0182191. <https://doi.org/10.1371/journal.pone.0182191>.
- 496
- 497 25. Maruyama T, Fujisawa T, Suga S, Nakamura H, Nagao M, Taniguchi K, et al. Outcomes
498 and Prognostic Features of Patients With Influenza Requiring Hospitalization and
499 Receiving Early Antiviral Therapy: A Prospective Multicenter Cohort Study. *Chest*.
500 2016; 149(2):526-534.doi: 10.1378/chest.14-2768.
- 501 26. Leung NHL, Chu DKW, Shiu EYC, Chan KH, McDevitt JJ, Hau JPB et al. Respiratory
502 virus shedding in exhaled breath and efficacy of face masks. *Nat Med* 2020; 26, 676–680
503 <https://doi.org/10.1038/s41591-020-0843-2>.

- 504 27. Sakamoto H, Ishikane M, Ueda P. Seasonal Influenza Activity During the SARS-CoV-2
505 Outbreak in Japan. 2020. JAMA. 2020;323(19):1969-1971. doi:10.1001/jama.2020.617.
- 506 28. Yue H, Zhang M, Xing L, Wang K, Rao X, Liu H, Tian J, Zhou P, Deng Y, Shang J.
507 The epidemiology and clinical characteristics of coinfection of SARS-CoV-2 and
508 influenza viruses in patients during COVID-19 outbreak. J Med Virol 2020.
509 92(11):2870-2873. doi: 10.1002/jmv.26163.
- 510 29. Li X, Li J, Meng L, Zhu W, Liu X, Yang M, Yu D, Niu L, Shen X. Viral etiologies and
511 epidemiology of patients with acute respiratory infections based on sentinel hospitals in
512 Gansu Province, Northwest China, 2011-2015. J Med Virol 2018;90(5):828–35.
- 513 30. Ren L, Gonzalez R, Wang Z, Xiang Z, Wang Y, Zhou H et al. Prevalence of human
514 respiratory viruses in adults with acute respiratory tract infections in Beijing, 2005-2007.
515 Clin Microbiol Infect 2009; 15(12):1146–53.
- 516 31. Wu X, Cai Y, Huang X, Yu X, Zhao L, Wang F, Li Q, Gu S, Xu T, Li Y, et al.
517 Coinfection with SARS-CoV-2 and Influenza A virus in patient with pneumonia, China.
518 Emerg Infect Dis 2020;26(6):1324–6.
- 519 32. Touzard-Romo F, Tapé C, Lonks JR. Coinfection with SARS-CoV-2 and Human
520 Metapneumovirus. Rhode Island Med J 2020;103(2):75–6.